Creative Biolabs offers lentivirus-like particles services, providing customized, scalable solutions for gene delivery. Their services ensure high transduction efficiency and safety, ideal for therapeutic applications and research in gene therapy and functional genomics.
VLPs that carry RNP payloads take benefit of viral delivery's efficiency and tissue targeting while avoiding the dangers associated with viral genome integration and long-term editing agent expression. Lentiviruses are a popular scaffold for VLP packaging due to their flexible structure and large particle size, which can accommodate non-natural protein cargo, and their tropism can be modified by pseudotyping virions with various envelope glycoproteins. Therefore, lentivirus-enveloped VLP (LVLP), can target specific cells. LVLPs are widely used to deliver gene editors to avoid the long-term expression of nucleases mediated by lentiviral vectors will increase the off-target effects of gene editing, to achieve the transient expression of gene editing proteins. Creative Biolabs developed two main strategies for LVLP packaging of mRNA:
LVLPs are commonly employed in gene editing because of their ability to dramatically reduce off-target and immunogenicity. Figure 1 depicts the development of a new mRNA delivery technique based on a lentiviral system. This technique uses RNA aptamers and aptamer-binding proteins for LVLP packaging of mRNA that encodes one of the longest Cas9 proteins (SpCas9) and vascular endothelial growth factor A, Vegfa's sgRNA, to treat disorders caused by Vegfa-induced wet age-related macular degeneration. After subretinal injections in mice, LVLP-CRISPR effectively edits 44% of the Vegfa gene in the retinal pigment epithelium cell and reduces 63% of new blood vessels. In addition, The Cas9 mRNA delivered lasts only 72 hours, reducing the risk of off-target and immune responses. This highlights the potential of LVLP delivery vectors for safe and effective gene editing technology.
Fig.1 The packaging process of LVLP for co-delivery of Cas9 mRNA and sgRNA.1
Creative Biolabs is committed to offering LVLP services for worldwide customers. Our services encompass custom plan development tailored to customer specifications and LVLP attributes, lentiviral vector manufacturing, VLP assembly and purification, protein expression assessment, and more. For comprehensive details, please reach out to us. We are committed to providing the most suitable service for your project needs.
Inquire About Our ServicesA: LLPs are viral mimics that deliver genetic material without viral replication capabilities, used primarily for gene therapy, vaccine development, and basic research in genetic manipulation.
A: Yes, Creative Biolabs offers customized LLPs services tailored to specific delivery targets, gene constructs, and clinical applications, ensuring optimal integration and expression of genetic material.
A: Creative Biolabs' LLPs are designed with multiple safety features, including deletion of viral genes associated with replication and pathogenesis, ensuring safe use in both clinical and research settings.
A: LLPs can deliver a wide range of genetic materials, including DNA, shRNA, mRNA, or CRISPR components, tailored to client needs for diverse applications such as gene knockdown, protein expression, or gene editing.
A: Creative Biolabs' LLPs are engineered to maximize transduction efficiency across a variety of cell types, including hard-to-transfect cells, thereby enhancing the efficacy of genetic interventions.
In the experiment, lentivirus-like particles (LVLPs) were developed to package SaCas9 mRNA for efficient gene editing. The role of LVLPs was to deliver SaCas9 mRNA transiently into target cells, ensuring high levels of genome editing activity with reduced off-target effects. The results demonstrated that LVLPs could package SaCas9 mRNA efficiently, achieving a significant indel rate (86.5%) in target sequences and lower off-target rates compared to other viral vectors like AAV and lentivirus. Additionally, LVLPs showed high transduction efficiency and the ability to target multiple genes in various cell types, confirming their potential as a safer and effective tool for transient gene editing.
Fig.2 Developing LVLPs for SaCas9 mRNA packaging.2
| Cat. No | Product Name | Promoter |
|---|---|---|
| CAT#: GTVCR-WQ001MR | IVTScrip™ pT7-mRNA-EGFP Vector | T7 |
| CAT#: GTVCR-WQ002MR | IVTScrip™ pT7-VEE-mRNA-EGFP Vector | T7 |
| CAT#: GTVCR-WQ003MR | IVTScrip™ pT7-VEE-mRNA-FLuc Vector | T7 |
| CAT#: GTVCR-WQ87MR | IVTScrip™ pT7-VEE-mRNA-Anti-SELP, 42-89-glycoprotein Vector | T7 |
| Cat. No | Product Name | Type |
|---|---|---|
| CAT#: GTTS-WQ001MR) | IVTScrip™ mRNA-EGFP (Cap 1, 30 nt-poly(A)) | Reporter Gene |
| CAT#: GTTS-WK18036MR | IVTScrip™ mRNA-Human AIMP2, (Cap 1, Pseudo-UTP, 120 nt-poly(A)) | Enzyme mRNA |
| (CAT#: GTTS-WQ004MR) | IVTScrip™ mRNA-Fluc (Cap 1, 30 nt-poly(A)) | Reporter Gene |
| (CAT#: GTTS-WQ009MR) | IVTScrip™ mRNA-β gal (Cap 1, 30 nt-poly(A)) | Reporter Gene |
References
